Cardiovascular benefit of oral semaglutide in patients with T2DM and established atherosclerotic cardiovascular diseases and/or chronic kidney disease is currently under investigation in SOUL (Semaglutide cardiovascular outcomes) trial (45)
Highlights Glucagon-like peptide-1 receptor agonists are effective for weight loss in post-bariatric surgery
These food-based GLP-1 strategies may support microbial fermentation, satiety signaling, and metabolic balance as part of a broader diet-first approach
Each receptor system contributes distinct metabolic effects and GLP-1 influencing insulin secretion and appetite, GIP influencing incretin response and fat cell biology, and glucagon driving energy expenditure and hepatic fat metabolism
Im honored to engage around the Sepsis Alliance Symposium: a critical platform uniting clinicians, #laboratorians, #pharmacists, researchers, and #healthcare leaders to improve diagnostic accuracy and patient outcomes
Benefits Mimics natural human growth hormone Reduces visceral fat, significantly diminishing abdominal fat Increases lean muscle mass Reduces liver fat in NAFLD Improves lipid profile when taken over 6 12 months Improves cognition related to age-related GH/IGF-1 decline Dosing Subcutaneous 1,000 mcg 2,000 mcg Once daily At bedtime 12 weeks ON
